Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telix Pharmaceuticals ( (AU:TLX) ) has provided an update.
Telix Pharmaceuticals has announced the lapse of several classes of conditional securities, including 45,000 share rights (TLXAP), 326,334 share appreciation rights (TLXAO), and 84,896 US performance share appreciation rights (TLXAW), all of which ceased on 30 October 2025 after their vesting conditions were not met or became incapable of being satisfied. The cessation of these rights reduces potential future equity dilution and indicates that certain performance or service conditions tied to these incentives were not achieved, marginally simplifying the company’s capital structure and refining the alignment between management incentives and shareholder outcomes.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$25.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited, listed on the ASX under the code TLX, operates in the pharmaceuticals and biotechnology sector, with a focus on developing and commercialising medical products, including advanced therapeutics and diagnostics. The company’s securities structure includes various share rights and share appreciation rights granted as part of its capital management and incentive arrangements.
YTD Price Performance: 0.36%
Average Trading Volume: 1,775,869
Technical Sentiment Signal: Sell
Current Market Cap: A$3.81B
Learn more about TLX stock on TipRanks’ Stock Analysis page.